Results 171 to 180 of about 28,857 (204)

Ibrexafungerp for the treatment of vulvovaginal candidiasis

Drugs of Today, 2022
Worldwide, effective management of vulvovaginal candidiasis (VVC) continues to serve as a major therapeutic goal with numerous unmet drug treatment challenges. After 3 decades of azole drug dominance, with few recent new antifungal agents and little progress in VVC management, the first-in-class oral triterpenoid glucan synthase inhibitor agent ...
openaire   +2 more sources

A serologic test for vulvovaginal candidiasis

International Journal of Gynecology & Obstetrics, 2003
Vulvovaginal candidiasis (VVC) is a common medical problem affecting many women in the community w1–3x. The diagnosis of VVC remains problematic. Clinical features of VVC are nonspecific, and the standard laboratory test to identify Candida organisms from a vaginal swab may take between 5 to 7 days to confirm the diagnosis. Thus, as many as half of the
S W, Tan, A, Mackay, J, Warmington
openaire   +2 more sources

Vulvovaginal Candidiasis: Treatment and Recurrence

Australian and New Zealand Journal of Obstetrics and Gynaecology, 1982
Summary: This study compares the effectiveness of 6 treatment regimens for vulvovaginal candidiasis with 6 months' follow‐up. 292 patients randomly allocated to the treatments completed the trial. Significant differences were found in the rates of recurrence within the different treatment groups.
G J, Dennerstein, R, Langley
openaire   +2 more sources

Candidiasis (vulvovaginal).

Clinical evidence, 2005
Vulvovaginal candidiasis is estimated to be the second most common cause of vaginitis after bacterial vaginosis. Candida albicans accounts for 85% to 90% of cases.We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments for acute vulvovaginal candidiasis in non-pregnant symptomatic ...
openaire   +5 more sources

Pathogenesis of recurrent vulvovaginal candidiasis

Current Infectious Disease Reports, 2002
Recurrent vulvovaginal candidiasis (RVVC) is by no means uncommon and is a source of considerable physical suffering, in addition to serving as a major therapeutic challenge. The syndrome is multifactorial in etiology, hence management strategies must recognize the complex etiologic pathways. Considerable progress has been made in identifying secondary
openaire   +2 more sources

Vulvovaginal Candidiasis and Bacterial Vaginosis

Infectious Disease Clinics of North America, 2008
Vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV) are frequently encountered in clinical practice. Recent advances have furthered understanding of pathophysiology. Proper diagnosis, based on appropriate office and, in complicated cases, laboratory tests is the key to rational selection of therapy.
openaire   +2 more sources

Managing Patients with Vulvovaginal Candidiasis

The Nurse Practitioner, 1998
Epidemiologic studies have demonstrated a continuing increase in the prevalence of vulvovaginal candidiasis. Although in the past most of these infections were caused by Candida albicans, an increasing percentage are caused by non-albicans Candida species that are less sensitive to the most frequently used antifungal agents.
openaire   +2 more sources

Classification and pathogenesis of vulvovaginal candidiasis

American Journal of Obstetrics and Gynecology, 1985
Although candidiasis of the female genital tract is one of the most common of the vaginitides, it is a poorly understood disease entity. Vulvovaginal candidiasis is a monoetiologic disease, but the pathways by which pathogenic expression is attained are sufficiently divergent to constitute a classification schema that influences therapy.
openaire   +2 more sources

Pathogenesis and Epidemiology of Vulvovaginal Candidiasis

Annals of the New York Academy of Sciences, 1988
In contrast to women with infrequent episodes of candidal vaginitis, women with chronic and recurrent candidal vaginitis do not have recognizable precipitating or causal factors. Analysis of vaginal yeast isolated from women with recurrent candidal vaginitis, although revealing a higher percentage of non-albicans Candida sp., indicates that resistance ...
openaire   +2 more sources

Candidiasis (vulvovaginal).

BMJ clinical evidence, 2018
Vulvovaginal candidiasis is estimated to be the second most common cause of vaginitis after bacterial vaginosis. Candida albicans accounts for 85% to 90% of cases.We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments for acute vulvovaginal candidiasis in non-pregnant symptomatic ...
openaire   +1 more source